Login to Your Account



Mologen Shares Rise on Cancer Immunotherapy Phase II Data

By Cormac Sheridan
Staff Writer

Tuesday, May 15, 2012
Shares in Mologen AG jumped 17 percent to a 52-week high Monday on news that the company's DNA-based cancer immunotherapy, MGN1703, hit the primary endpoint, a prolongation of progression-free survival (PFS), in a Phase II trial in patients with metastatic colorectal cancer (CRC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription